Pantoprazole (Proton Pump Inhibitor) Contributing to Torsades de Pointes Storm

John N. Bibawy, MD; Valay Parikh, MBBS; Joseph Wahba, MD; Emad A. Barsoum, MD; James Lafferty, MD, FACC; Marcin Kowalski, MD, FACC, FRS; Soad Bekheit, MD, PhD, FACC, FRS

Proton pump inhibitors (PPI), commonly used medications for peptic ulcer prophylaxis, have been recently described to cause hypomagnesemia through both urinary and gastrointestinal losses. Very few reports have linked hypomagnesemia with life-threatening ventricular arrhythmias. However, these reports included patients with other complex medical problems that may have also contributed to these arrhythmias. To our knowledge, ventricular arrhythmias associated with hypomagnesemia induced by proton pump inhibitors have never been reported. We present a case of a 53-year-old chronic alcoholic male patient, who was started on a proton pump inhibitor for peptic ulcer prophylaxis, which resulted in resistant hypomagnesemia associated with a storm of life-threatening arrhythmias, namely Torsades de Pointes (TdP).

Case Report
A 53-year-old man with no previous cardiac history was brought by Emergency Medical Services with a chief complaint of palpitations and dizziness for 1 day. His only significant medical history was chronic alcohol abuse and was not taking any medications before his admission. His physical examination was normal, except for an irregularly irregular rapid pulse and a blood pressure of 157/104 mm Hg. The ECG on admission showed atrial fibrillation with a QTc of 0.38 s. Patient remains well during his 1-year follow-up.

On day 16 of admission, pantoprazole was discontinued. Three days after the cessation of pantoprazole, the QTc shortened to a daily average of 0.457±0.0275 s until the day of discharge (Day 41; Figure 3). Together with the shortening of the QT interval, the daily requirements of magnesium supplementation were significantly reduced to an average of 2 g per day. There were no recurrences of pVT or TdP after the discontinuation of pantoprazole (Figure 4). Coronary angiography was also performed during this admission, and it showed no coronary artery disease. Follow-up after 1 month showed a normal ECG with a QTc of 0.38 s. Patient remains well during his 1-year follow-up.

Discussion
The question of whether hypomagnesemia results in cardiac arrhythmias remains unsolved, largely because of the absence of associated ECG and clinical electrophysiological changes. However, few ECG changes caused by hypomagnesemia


DOI: 10.1161/CIRCEP.112.000101
were described in the setting of acute myocardial infarction by Dyckner et al.¹ These changes included widening of QRS complexes, peaking of T waves in mild magnesium losses, prolongation of the PR interval, and diminution of T waves in severe magnesium losses. Ventricular tachycardia and TdP were also reported in a few cases of magnesium deficiency.² However, these cases had other contributing factors that may have caused the cardiac arrhythmia in these patients.

Intracellular magnesium and magnesium-ATP have been shown to play an important regulatory role on potassium and calcium channels in animal experiments. Experimentally, cytosolic magnesium has been described to influence the inward rectification of the potassium channels (Ikr) by plugging the opened channels as well as modulating the outwardly directed potassium current (Ito), thereby allowing the potassium current to repolarize the myocardial cell. Inhibition of the Ikr channel is the most common cause of prolonged QT leading to TdP. Another possible mechanism of prolonged QT caused by hypomagnesemia could be through its effect on the membrane ATP-ase, which provides the energy for transport of sodium out of the cell and potassium into the cell.¹ Thus, magnesium deficiency, theoretically, will lead to intracellular potassium loss. With a cellular loss of potassium, repolarization of the cell will change, resulting in a prolonged QT interval. On the other hand, magnesium exerts its salutary effect on the treatment of ventricular arrhythmias associated

Figure 1. Torsades de Pointes on Day 1, Day 8, and Day 12 of admission.

Figure 2. T wave alternans on Day 1 of admission, QT = 0.62 s (QTc = 0.65 s) alternating with QT = 0.46 s (QTc = 0.51 s).

Figure 3. On day 19, 3 days after stopping pantoprazole, a shortening of the QT interval was noticed. Sinus Rhythm, heart rate = 67 beats per minute, QT = 0.4 s (QTc = 0.43 s).

Figure 4. Graph comparing magnesium supplementation (g) with QTc (s) as well as arrhythmic events.
Our patient experienced frequent episodes of fatal arrhythmias, namely TdP during his hospitalization. The only electrolyte abnormality noted was intractable hypomagnesemia. Hypomagnesemia in our patient can be attributed to 2 additive causes, namely chronic alcoholism and the use of PPI therapy. Hypomagnesemia can occur in chronic alcoholism because of renal losses as well as gastrointestinal malnutrition, which tends to resolve within 4 weeks of abstinence from alcohol. Recently, it has been shown that patients taking PPIs have a 2.5-fold increased risk of hypomagnesemia, which occurs through both renal and gastrointestinal losses. Despite the abstinence of alcohol intake, our patient continued to have persistent QT prolongation causing TdP until the discontinuation of pantoprazole on day 16 of admission. This is in concordance with the significant reduction in the daily requirement of the IV magnesium supplementation to maintain a QTc with an acceptable duration (Figure 4).

In summary, we conclude that the addition of a PPI, which is the standard of care in critically ill patients, should be used with caution in patients who have a previous tendency to hypomagnesemia, as in our patient. In these patients, PPIs can potentiate the hypomagnesemia-induced lethal arrhythmias, which can result in sudden cardiac death. PPI therapy can potentially be dangerous in critically ill patients who are prone to electrolyte and nutritional abnormalities.

Disclosures

None.

References


Key Words: arrhythmia • hypomagnesemia • pantoprazole • proton pump inhibitors • torsades de pointes
Pantoprazole (Proton Pump Inhibitor) Contributing to Torsades de Pointes Storm
John N. Bibawy, Valay Parikh, Joseph Wahba, Emad A. Barsoum, James Lafferty, Marcin Kowalski and Soad Bekheit

Circ Arrhythm Electrophysiol. 2013;6:e17-e19
doi: 10.1161/CIRCEP.112.000101

Circulation: Arrhythmia and Electrophysiology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/6/2/e17